Guselkumab-Treated Patients with Plaque Psoriasis Who Achieved Complete Skin Clearance for = 156 Consecutive Weeks: A Post-Hoc Analysis From the VOYAGE 1 Clinical Trial
Por:
Puig L, Costanzo A, de Jong EMGJ, Torres T, Warren RB, Wapenaar R, Wegner S, Gorecki P, Gramiccia T, Jazra M, Buyze J, Conrad C
Publicada:
1 mar 2024
Ahead of Print:
1 oct 2023
Resumen:
Background Treatment of moderate-to-severe plaque psoriasis with biologics, such as guselkumab, has demonstrated greater efficacy over traditional non-biologic treatments. However, given patient diversity, greater understanding of the relationship between patient characteristics, positive clinical outcomes, and long-term response to biologics is crucial for optimizing treatment choices.Materials and Methods This post-hoc analysis of the 5-year VOYAGE 1 clinical trial compares baseline characteristics of patients maintaining a Psoriasis Area and Severity Index (PASI) score of 0 at all visits for >= 156 consecutive weeks (PASI = 0 group) with those that never achieve PASI = 0 (comparator group), using descriptive statistics and a multiple logistic regression model. Guselkumab plasma trough concentrations in both response groups were assessed from Weeks 4-156.Results Of patients who started guselkumab treatment at Week 0 or at Week 16 after switching from placebo, 22.7% (112/494) maintained PASI = 0 for >= 156 consecutive weeks. Numerical differences in baseline characteristics, including age, obesity, diabetes, PASI score, disease duration, smoking status, and psoriatic arthritis comorbidity, were identified between the PASI = 0 group and comparator group. Plasma guselkumab levels were consistently higher in the PASI = 0 group. Multiple logistic regression analysis revealed absence of diabetes, lower Dermatology Life Quality Index score at baseline, and higher Week 4 guselkumab plasma concentration as significantly (p < 0.05) associated with the PASI = 0 group.Conclusion A substantial (22.7%) number of guselkumab-treated patients in the VOYAGE 1 clinical trial maintained complete skin clearance for a consecutive period of >= 156 weeks. Factors associated with this outcome may suggest clinical benefits of holistic treatment approaches.
Filiaciones:
Puig L:
Department of Dermatology, IIB Sant Pau, Hospital de Santa Creu i Sant Pau, Universitat Autònoma de Barcelona, Barcelona, Spain.
Costanzo A:
Dermatology, Department of Biomedical Sciences, Humanitas University, Milan, Italy
Humanitas Clinical and Research Center IRCCS, Milan, Italy
de Jong EMGJ:
Department of Dermatology, Radboud University Medical Center, Nijmegen, The Netherlands
Torres T:
Centro Hospitalar Universitário do Porto, Porto, Portugal
Institute of Biomedical Sciences Abel Salazar, University of Porto, Porto, Portugal
Warren RB:
Dermatology Centre, Salford Royal NHS Foundation Trust, National Institute for Health Research Manchester Biomedical Research Centre, The University of Manchester, Manchester, UK
Wapenaar R:
Janssen-Cilag BV, Breda, The Netherlands
Wegner S:
Janssen-Cilag GmbH, Neuss, Germany
Gorecki P:
Janssen-Cilag Ltd, High Wycombe, UK
Gramiccia T:
Janssen-Cilag SpA, Milan, Italy
Jazra M:
Janssen-Cilag, Paris, France
Buyze J:
Janssen Pharmaceutica NV, Beerse, Belgium
Conrad C:
Department of Dermatology, Lausanne University Hospital CHUV and University of Lausanne, Lausanne, Switzerland
Green Published, hybrid, All Open Access; Hybrid Gold
|